Computational design of a multi-epitope vaccine candidate against Langya henipavirus using surface proteins
In July 2022, Langya henipavirus (LayV) was identified in febrile patients in China. There is currently no approved vaccine against this virus. Therefore, this research aimed to design a multi-epitope vaccine against LayV using reverse vaccinology. The best epitopes were selected from LayV's fusion protein (F) and glycoprotein (G), and a multi-epitope vaccine was designed using these epitopes, adjuvant, and appropriate linkers. The physicochemical properties, antigenicity, allergenicity, toxicity, and solubility of the vaccine were evaluated. The vaccine's secondary and 3D structures were predicted, and molecular docking and molecular dynamics (MD) simulations were used to assess the vaccine's interaction and stability with toll-like receptor 4 (TLR4). Immune simulation, codon optimization, and in silico cloning of the vaccine were also performed. The vaccine candidate showed good physicochemical properties, as well as being antigenic, non-allergenic, and non-toxic, with acceptable solubility. Molecular docking and MD simulation revealed that the vaccine and TLR4 have stable interactions. Furthermore, immunological simulation of the vaccine indicated its ability to elicit immune responses against LayV. The vaccine's increased expression was also ensured using codon optimization. This study's findings were encouraging, but in vitro and in vivo tests are needed to confirm the vaccine's protective effect.Communicated by Ramaswamy H. Sarma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Journal of biomolecular structure & dynamics - (2023) vom: 15. Sept., Seite 1-18 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ahmad, Sajjad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adjuvant |
|---|
| Anmerkungen: |
Date Revised 15.09.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/07391102.2023.2258403 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362104840 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362104840 | ||
| 003 | DE-627 | ||
| 005 | 20231226090534.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/07391102.2023.2258403 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1206.xml |
| 035 | |a (DE-627)NLM362104840 | ||
| 035 | |a (NLM)37713338 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ahmad, Sajjad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Computational design of a multi-epitope vaccine candidate against Langya henipavirus using surface proteins |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a In July 2022, Langya henipavirus (LayV) was identified in febrile patients in China. There is currently no approved vaccine against this virus. Therefore, this research aimed to design a multi-epitope vaccine against LayV using reverse vaccinology. The best epitopes were selected from LayV's fusion protein (F) and glycoprotein (G), and a multi-epitope vaccine was designed using these epitopes, adjuvant, and appropriate linkers. The physicochemical properties, antigenicity, allergenicity, toxicity, and solubility of the vaccine were evaluated. The vaccine's secondary and 3D structures were predicted, and molecular docking and molecular dynamics (MD) simulations were used to assess the vaccine's interaction and stability with toll-like receptor 4 (TLR4). Immune simulation, codon optimization, and in silico cloning of the vaccine were also performed. The vaccine candidate showed good physicochemical properties, as well as being antigenic, non-allergenic, and non-toxic, with acceptable solubility. Molecular docking and MD simulation revealed that the vaccine and TLR4 have stable interactions. Furthermore, immunological simulation of the vaccine indicated its ability to elicit immune responses against LayV. The vaccine's increased expression was also ensured using codon optimization. This study's findings were encouraging, but in vitro and in vivo tests are needed to confirm the vaccine's protective effect.Communicated by Ramaswamy H. Sarma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Langya henipavirus | |
| 650 | 4 | |a adjuvant | |
| 650 | 4 | |a epitope | |
| 650 | 4 | |a reverse vaccinology | |
| 650 | 4 | |a vaccine | |
| 700 | 1 | |a Nazarian, Shahin |e verfasserin |4 aut | |
| 700 | 1 | |a Alizadeh, Akram |e verfasserin |4 aut | |
| 700 | 1 | |a Pashapour Hajialilou, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Tahmasebian, Shahram |e verfasserin |4 aut | |
| 700 | 1 | |a Alharbi, Metab |e verfasserin |4 aut | |
| 700 | 1 | |a Alasmari, Abdullah F |e verfasserin |4 aut | |
| 700 | 1 | |a Shojaeian, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Ghatrehsamani, Mahdi |e verfasserin |4 aut | |
| 700 | 1 | |a Irfan, Muhammad |e verfasserin |4 aut | |
| 700 | 1 | |a Pazoki-Toroudi, Hamidreza |e verfasserin |4 aut | |
| 700 | 1 | |a Sanami, Samira |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of biomolecular structure & dynamics |d 1985 |g (2023) vom: 15. Sept., Seite 1-18 |w (DE-627)NLM012639974 |x 1538-0254 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:15 |g month:09 |g pages:1-18 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/07391102.2023.2258403 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 15 |c 09 |h 1-18 | ||